Inventor
MELAMED ELDAD
IL25 patents
⚠️ This page may combine multiple inventors who share the name “MELAMED ELDAD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
YISSUM RES DEV CO
5 patentsUS6369106B1Apr 9, 2002
Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
YISSUM RES DEV CO62 citations95
US5607969AMar 4, 1997
L-DOPA ethyl ester to treat Parkinson's disease
YISSUM RES DEV CO80 citations94
US6420429B1Jul 16, 2002
Brain targeted low molecular weight hydrophobic antioxidant compounds
YISSUM RES DEV CO38 citations92
US5525631AJun 11, 1996
Compositions of the ethyl ester of L-DOPA
YISSUM RES DEV CO24 citations90
US5354885AOct 11, 1994
Process for preparing ethyl ester of L-DOPA
YISSUM RES DEV CO42 citations90
UNIV RAMOT
5 patentsUS8900574B2Dec 2, 2014
Mesenchymal stem cells for the treatment of CNS diseases
UNIV RAMOT5 citations82
US11185572B2Nov 30, 2021
Mesenchymal stem cells for the treatment of CNS diseases
UNIV RAMOT0 citations60
US10052363B2Aug 21, 2018
Mesenchymal stem cells for the treatment of CNS diseases
UNIV RAMOT1 citations60
US10869899B2Dec 22, 2020
Isolated cells and populations comprising same for the treatment of CNS diseases
UNIV RAMOT0 citations51
US8378070B2Feb 19, 2013
Peptides for the regulation of neurotransmitter sequestration and release
UNIV RAMOT0 citations48
RAMOT AT TEL-AVIV UNIV LTD
4 patentsUS9474787B2Oct 25, 2016
Mesenchymal stem cells for the treatment of CNS diseases
RAMOT AT TEL-AVIV UNIV LTD4 citations82
US9717761B2Aug 1, 2017
Stem cell-derived neural cells for cell therapy in neurological disorders
RAMOT AT TEL-AVIV UNIV LTD3 citations70
US9879225B2Jan 30, 2018
Isolated cells and populations comprising same for the treatment of CNS diseases
RAMOT AT TEL-AVIV UNIV LTD0 citations51
US10744162B2Aug 18, 2020
Genetically modified muscle cells which express neurotrophic factors
RAMOT AT TEL-AVIV UNIV LTD0 citations42
OFFEN DANIEL
4 patentsUS8647874B2Feb 11, 2014
Isolated cells and populations comprising same for the treatment of CNS diseases
OFFEN DANIEL5 citations82
US9023800B2May 5, 2015
Peptides for the treatment of oxidative stress related disorders
OFFEN DANIEL1 citations48
US8212001B2Jul 3, 2012
Peptides for the treatment of oxidative stress related disorders
OFFEN DANIEL1 citations48
US9365828B2Jun 14, 2016
Genetically modified muscle cells which express neurotrophic factors
OFFEN DANIEL0 citations41